Program
pelareorep
Also written as “REOLYSIN®”, “REOLYSIN” and “Pelareorep”.
Its studies are mostly in Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Squamous Cell Carcinoma of Head and Neck · Anus Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Oncolytics Biotech | 132 open or running | phase 3since Jul 13, 2010 | Jul 16, 2007 | Jul 30, 2027phase 2 · NCT07280377 |
| Adlai Nortye Biopharma | 10 open or running | phase 1since Aug 25, 2022 | Aug 25, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2007First study: phase 2 study in OsteosarcomaNew to Oncolytics BiotechOncolytics Biotech · NCT00503295 · 53 enrolled · United States
- Sep 10, 2007Phase 1 study in GliomaOncolytics Biotech · NCT00528684 · 18 enrolled · United States
- Sep 12, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckOncolytics Biotech · NCT00753038 · 14 enrolled · United States
- Mar 12, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungOncolytics Biotech · NCT00861627 · 37 enrolled · United States
- Sep 24, 2009Phase 2 study in MelanomaOncolytics Biotech · NCT00984464 · 14 enrolled · United States
- Oct 15, 20092 phase 2 studies in Neoplasm MetastasisOncolytics Biotech · NCT00998322, NCT00998192
- Jul 13, 2010Phase 3 study in Squamous Cell Carcinoma of Head and NeckOncolytics Biotech · NCT01166542 · 167 enrolled · United States, Belgium, Canada and more
- Jan 7, 2011Phase 1 study in NeoplasmsOncolytics Biotech · NCT01274624 · 36 enrolled · United States
- Nov 25, 2015Phase 1 study in NeoplasmsOncolytics Biotech · NCT02620423 · 11 enrolled · United States
- Mar 24, 2016Phase 1 study in NeoplasmsOncolytics Biotech · NCT02723838
- Dec 24, 2019Phase 2 study in Breast NeoplasmsOncolytics Biotech · NCT04215146 · 48 enrolled · United States
- Aug 25, 2022Adlai Nortye Biopharma's first study: phase 1 study in Breast NeoplasmsNew to Adlai Nortye BiopharmaAdlai Nortye Biopharma · NCT05519059 · 15 enrolled · China
- Nov 18, 2025Phase 2 study in Anal Cancer MetastaticOncolytics Biotech · NCT07280377 · 122 enrolled · Germany
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Anal Cancer MetastaticOncolytics Biotech · NCT07280377
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07280377Anal Cancer Metastatic · Germany | 2 | Active, not recruiting | Oncolytics Biotech | Jul 30, 2027 | 122 |
| NCT05519059Breast Neoplasms · China | 1 | Completed | Adlai Nortye Biopharma | Sep 29, 2022 | 15 |
| NCT04215146Breast Neoplasms · United States | 2 | Active, not recruiting | Oncolytics Biotech | Aug 1, 2022 | 48 |
| NCT02723838Neoplasms | 1 | Withdrawn | Oncolytics Biotech | Sep 30, 2017 | 0 |
| NCT02620423Neoplasms · United States | 1 | Completed | Oncolytics Biotech | Mar 2018 | 11 |
| NCT01274624Neoplasms · United States | 1 | Completed | Oncolytics Biotech | Feb 2018 | 36 |
| NCT01166542Squamous Cell Carcinoma of Head and Neck · United States, Belgium, Canada and more | 3 | Completed | Oncolytics Biotech | Apr 2012 | 167 |
| NCT00998322Neoplasm Metastasis · United States | 2 | Completed | Oncolytics Biotech | Dec 2013 | 34 |
| NCT00998192Neoplasm Metastasis · United States | 2 | Completed | Oncolytics Biotech | Sep 2013 | 32 |
| NCT00984464Melanoma · United States | 2 | Completed | Oncolytics Biotech | Feb 2014 | 14 |
| NCT00861627Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Oncolytics Biotech | Sep 2015 | 37 |
| NCT00753038Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | Oncolytics Biotech | Jul 2011 | 14 |
| NCT00528684Glioma · United States | 1 | Completed | Oncolytics Biotech | Apr 2010 | 18 |
| NCT00503295Osteosarcoma · United States | 2 | Completed | Oncolytics Biotech | Feb 2011 | 53 |
How it is read
Names in the registry
- “REOLYSIN®”, 7 entries
- “REOLYSIN”, 4 entries
- “Pelareorep”, 3 entries
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Breast Neoplasms, 2 studies
- Neoplasm Metastasis, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Anus Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.